Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with
systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Background. Interstitial lung disease (ILD) is the most common complication of systemic
sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta‐analysis was to …

Objective Our objective was to determine if treatment with cyclophosphamide (CYC) and
mycophenolate mofetil (MMF) improves patient‐reported outcomes (PROs) among patients …

Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients
with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational …

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Background Scleroderma is a systemic autoimmune disease characterized mainly by skin
manifestations and involvement of various visceral organs, especially the lungs. Lung …